A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy

About A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy

In this activity, Jeremy Abramson, MD, highlights the significant disease burden of B-cell lymphomas, as well as the latest advances in therapeutics, and practical strategies for integrating novel therapies into practice through patient selection and supportive care management.

Publisher

Annenberg Center for Health Sciences

Category

health & fitness

Language

en

Explicit

No

First episode

9 Jun 2022

Latest episode

9 Jun 2022

Latest episodes

4 episodes in the feed.

1. 

   9 Jun 2022

   Principles of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma: Patient Selection Strategies

   Large B-cell lymphomas (LBCLs) are one of the most common subtypes of non-Hodgkin lymphomas and while 1st-line standard of care has remained unchanged, the treatment paradigm has undergone a shift in recent years due to the development of novel therapeutic agents. These novel therapies include monoclonal antibody (mAb) therapies, mAb-conjugates, and chimeric antigen receptor (CAR)-T cell therapies.

2. 

   9 Jun 2022

   Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies

   Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies

3. 

   9 Jun 2022

   Disease Burden and Overview of Large B-Cell Lymphomas

   B-cell lymphomas consist of a heterogenous group of lymphoproliferative neoplasms originating from B-lymphocytes.

4. 

   9 Jun 2022

   Management of Adverse Effects Associated With Novel Therapies

   Management of relapsed/refractory LBCLs remains a substantial and persistent clinical challenge, including optimal treatment sequencing, therapy evaluation and patient selection, and toxicity management.

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Apple Podcasts (US)

5.0 / 5

1 ratings

Contact A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.